Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1515217rdf:typepubmed:Citationlld:pubmed
pubmed-article:1515217lifeskim:mentionsumls-concept:C0019704lld:lifeskim
pubmed-article:1515217lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1515217lifeskim:mentionsumls-concept:C0679729lld:lifeskim
pubmed-article:1515217lifeskim:mentionsumls-concept:C1513895lld:lifeskim
pubmed-article:1515217lifeskim:mentionsumls-concept:C0920472lld:lifeskim
pubmed-article:1515217lifeskim:mentionsumls-concept:C0086047lld:lifeskim
pubmed-article:1515217lifeskim:mentionsumls-concept:C0015737lld:lifeskim
pubmed-article:1515217lifeskim:mentionsumls-concept:C0205438lld:lifeskim
pubmed-article:1515217pubmed:issue5lld:pubmed
pubmed-article:1515217pubmed:dateCreated1992-10-6lld:pubmed
pubmed-article:1515217pubmed:abstractTextThis summary describes current studies in antiviral targeting as reported at the Frontiers in HIV Therapy conference, November 3-7, 1991, in San Diego, California. In parallel with the progressive steps in HIV-1 replication, the meeting covered potential antiviral targets starting from the time HIV-1 docks with the CD4 receptor to virus release. The summary concludes with current research trends to block HIV-1 growth.lld:pubmed
pubmed-article:1515217pubmed:languageenglld:pubmed
pubmed-article:1515217pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1515217pubmed:citationSubsetIMlld:pubmed
pubmed-article:1515217pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1515217pubmed:statusMEDLINElld:pubmed
pubmed-article:1515217pubmed:monthMaylld:pubmed
pubmed-article:1515217pubmed:issn0889-2229lld:pubmed
pubmed-article:1515217pubmed:authorpubmed-author:BridgerPPlld:pubmed
pubmed-article:1515217pubmed:authorpubmed-author:SarverNNlld:pubmed
pubmed-article:1515217pubmed:authorpubmed-author:BlackR JRJlld:pubmed
pubmed-article:1515217pubmed:authorpubmed-author:ChriseyLLlld:pubmed
pubmed-article:1515217pubmed:issnTypePrintlld:pubmed
pubmed-article:1515217pubmed:volume8lld:pubmed
pubmed-article:1515217pubmed:ownerNLMlld:pubmed
pubmed-article:1515217pubmed:authorsCompleteYlld:pubmed
pubmed-article:1515217pubmed:pagination659-67lld:pubmed
pubmed-article:1515217pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1515217pubmed:meshHeadingpubmed-meshheading:1515217-...lld:pubmed
pubmed-article:1515217pubmed:meshHeadingpubmed-meshheading:1515217-...lld:pubmed
pubmed-article:1515217pubmed:meshHeadingpubmed-meshheading:1515217-...lld:pubmed
pubmed-article:1515217pubmed:meshHeadingpubmed-meshheading:1515217-...lld:pubmed
pubmed-article:1515217pubmed:meshHeadingpubmed-meshheading:1515217-...lld:pubmed
pubmed-article:1515217pubmed:year1992lld:pubmed
pubmed-article:1515217pubmed:articleTitleFrontiers in HIV-1 Therapy: fourth conference of the NIAID National Cooperative Drug Discovery Groups-HIV.lld:pubmed
pubmed-article:1515217pubmed:affiliationDevelopmental Therapeutics Branch, National Institute of Allergy and Infectious Disease, Bethesda, MD.lld:pubmed
pubmed-article:1515217pubmed:publicationTypeCongresseslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1515217lld:pubmed